Mf. Tripodi et al., Treatment of pulmonary nocardiosis in heart-transplant patients: importance of susceptibility studies, CLIN TRANSP, 15(6), 2001, pp. 415-420
Pulmonary nocardiosis is an infrequent but insidious disease in transplant
patients. It has occurred in our centre in 3 out of 233 heart-transplant re
cipients since 1988. Common clinical features were mild symptoms and a seve
re nodular lung involvement. Early diagnosis was based upon cultures of bro
nchoalveolar lavage or fine-needle aspirate specimens of the lung lesions.
Susceptibility studies and tests of antibiotic synergism guided the therapy
. Two patients were treated with a combination of piperacillin-tazobactam a
nd ciproloxacin, and one with imipenem and amikacin, for 3-4 wk followed by
a 3-month course of trimethoprim-sulphamethoxazole. The nocardial disease
was successfully treated in the 3 patients; however, one died of subsequent
invasive pulmonary aspergillosis. In the absence of consensus on the lengt
h of therapy, this experience suggests that a synergistic combination of a
beta-lactam/beta-lactamase inhibitor with ciprofloxacin or amikacin followe
d by a short course of trimethoprim-sulphamethoxa-zole may be effective in
eradicating nocardial disease and may reduce the need for long-term treatme
nt.